[go: up one dir, main page]

UA110599C2 - Пептид для імунотерапії пухлин, включаючи нейрональні пухлини та пухлини мозку - Google Patents

Пептид для імунотерапії пухлин, включаючи нейрональні пухлини та пухлини мозку

Info

Publication number
UA110599C2
UA110599C2 UAA201103611A UAA201103611A UA110599C2 UA 110599 C2 UA110599 C2 UA 110599C2 UA A201103611 A UAA201103611 A UA A201103611A UA A201103611 A UAA201103611 A UA A201103611A UA 110599 C2 UA110599 C2 UA 110599C2
Authority
UA
Ukraine
Prior art keywords
tumors
peptide
immunotherapy
brain
amino acid
Prior art date
Application number
UAA201103611A
Other languages
English (en)
Inventor
Олівер Шор
Норберт Хільф
Тоні Вейншенк
Клаудія Траутвейн
Штеффен Вальтер
Харпреет Сінгх
Original Assignee
Імматікс Біотекнолоджіс Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Імматікс Біотекнолоджіс Гмбх filed Critical Імматікс Біотекнолоджіс Гмбх
Publication of UA110599C2 publication Critical patent/UA110599C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)

Abstract

Цей винахід належить до пептидів, нуклеїнових кислот та клітин для використання в імунотерапевтичних методах. Зокрема, цей винахід стосується пептиду, який містить послідовність амінокислот SEQ ID NO: 4, що викликає перехресне реагування Т-клітин із зазначеним пептидом; де зазначена послідовність амінокислот включає безперервну ділянку амінокислот відповідно до SEQ ID NO: 4, причому вказаний пептид має загальну довжину від 8 до 16 амінокислот.
UAA201103611A 2008-10-01 2009-09-28 Пептид для імунотерапії пухлин, включаючи нейрональні пухлини та пухлини мозку UA110599C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20080017305 EP2172211B1 (en) 2008-10-01 2008-10-01 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
PCT/EP2009/006980 WO2010037514A2 (en) 2008-10-01 2009-09-28 Novel immunotherapy against several tumors including neuronal and brain tumors

Publications (1)

Publication Number Publication Date
UA110599C2 true UA110599C2 (uk) 2016-01-25

Family

ID=40342382

Family Applications (3)

Application Number Title Priority Date Filing Date
UAA201500916A UA125277C2 (uk) 2008-10-01 2009-09-28 Пептид, активований цитотоксичний т-лімфоцит, спосіб одержання антитіла та лікарський засіб для імунотерапії раку
UAA201103612A UA103202C2 (uk) 2008-10-01 2009-09-28 Фармацевтична композиція пухлиноасоційованих пептидів та її застосування для лікування ракових захворювань
UAA201103611A UA110599C2 (uk) 2008-10-01 2009-09-28 Пептид для імунотерапії пухлин, включаючи нейрональні пухлини та пухлини мозку

Family Applications Before (2)

Application Number Title Priority Date Filing Date
UAA201500916A UA125277C2 (uk) 2008-10-01 2009-09-28 Пептид, активований цитотоксичний т-лімфоцит, спосіб одержання антитіла та лікарський засіб для імунотерапії раку
UAA201103612A UA103202C2 (uk) 2008-10-01 2009-09-28 Фармацевтична композиція пухлиноасоційованих пептидів та її застосування для лікування ракових захворювань

Country Status (25)

Country Link
US (19) US8119139B2 (uk)
EP (12) EP2172211B1 (uk)
JP (10) JP5753783B2 (uk)
KR (6) KR101883426B1 (uk)
CN (3) CN102170901B (uk)
AU (2) AU2009300087B2 (uk)
BR (2) BRPI0920791B8 (uk)
CA (9) CA2936920C (uk)
CY (11) CY1116302T1 (uk)
DK (12) DK2172211T3 (uk)
EA (3) EA023378B1 (uk)
ES (12) ES2536465T3 (uk)
HK (2) HK1159526A1 (uk)
HR (12) HRP20201025T8 (uk)
HU (11) HUE031030T2 (uk)
LT (10) LT2172212T (uk)
MX (3) MX2011003540A (uk)
NZ (4) NZ624533A (uk)
PL (12) PL2172211T3 (uk)
PT (12) PT2172211E (uk)
RS (12) RS53782B1 (uk)
SI (12) SI2172211T1 (uk)
TR (2) TR201900852T4 (uk)
UA (3) UA125277C2 (uk)
WO (2) WO2010037514A2 (uk)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435507B2 (en) 2004-08-19 2013-05-07 University Of Maryland Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer
US7612162B2 (en) 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
RS54204B1 (en) * 2007-07-27 2015-12-31 Immatics Biotechnologies Gmbh Novel immunotherapy against brain tumors
DE602008000891D1 (de) 2008-04-30 2010-05-12 Immatics Biotechnologies Gmbh Neuartige Formulierungen von Tumor-assoziierten Peptiden, welche an menschliche Leukozytenantigene der Klasse I oder II für Impfungen binden
PT2119726E (pt) 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
ES2536465T3 (es) * 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
TW201124530A (en) * 2009-12-01 2011-07-16 Oncotherapy Science Inc IMP-3 oligopeptides and vaccines including the same
SE535982C2 (sv) * 2009-12-15 2013-03-19 Theravac Pharmaceuticals Ab Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
AU2015200751B2 (en) * 2010-03-19 2016-11-10 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
ES2930809T3 (es) 2010-08-24 2022-12-22 Univ Pittsburgh Commonwealth Sys Higher Education Vacunas contra el cáncer cerebral basadas en el péptido receptor de interleucina-13 alfa 2
US20140017266A1 (en) * 2010-12-03 2014-01-16 The Government Of The United States, As Represented By The Secretary Of Hhs, Nih Anti-podoplanin antibodies and methods of use
SG191154A1 (en) * 2010-12-14 2013-07-31 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2013052158A2 (en) * 2011-04-26 2013-04-11 William Marsh Rice University Targeted nanovectors and their use for treatment of brain tumors
ES2856091T3 (es) * 2011-09-14 2021-09-27 Univ Northwestern Nanoconjugados capaces de atravesar la barrera hematoencefálica
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
CN115813902A (zh) * 2012-01-20 2023-03-21 德玛公司 经取代的己糖醇类用于治疗恶性肿瘤的用途
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CN103372217B (zh) * 2012-04-28 2014-12-10 中国科学院深圳先进技术研究院 聚合物纳米载体制剂及其制备方法和应用
SI3536334T1 (sl) 2012-05-16 2021-11-30 Stemline Therapeutics Inc. Cepiva proti raku, ki ciljajo na rakave matične celice
CN112587671A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
TWI714869B (zh) * 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
RS62602B1 (sr) * 2013-08-05 2021-12-31 Immatics Biotechnologies Gmbh Nova imunoterapija za lečenje nekoliko tumora, kao što je rak pluća, uključujući nsclc
MX2019013161A (es) * 2013-11-04 2020-02-03 Immatics Biotechnologies Gmbh Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
CN104698059B (zh) * 2013-12-04 2017-07-21 苏州中赢医疗科技有限公司 一种脑胶质瘤肿瘤标志物及其应用
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
EP3092049A1 (en) 2014-01-08 2016-11-16 Flodesign Sonics Inc. Acoustophoresis device with dual acoustophoretic chamber
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
US10774343B2 (en) 2014-04-25 2020-09-15 Bluebird Bio, Inc. MND promoter chimeric antigen receptors
JP6613526B2 (ja) * 2014-05-28 2019-12-04 学校法人東京女子医科大学 膠芽腫の予測方法
JP2015227292A (ja) * 2014-05-30 2015-12-17 国立大学法人高知大学 膵がん細胞浸潤転移抑制ワクチン
EP3151672B1 (en) 2014-06-06 2020-11-04 Bluebird Bio, Inc. Improved t cell compositions
JP6366379B2 (ja) * 2014-06-20 2018-08-01 キヤノン株式会社 被検体情報取得装置
CN106795217B (zh) 2014-07-24 2021-08-06 蓝鸟生物公司 Bcma嵌合抗原受体
JP6474893B2 (ja) * 2014-11-06 2019-02-27 オーエスイー・イミュノセラピューティクス 脳転移の処置のための治療用マルチペプチドｔ特異的免疫療法
SMT202100594T1 (it) 2014-12-12 2021-11-12 2Seventy Bio Inc Recettori chimerici dell'antigene bcma
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MA48487B1 (fr) 2014-12-23 2021-11-30 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
PH12021550910A1 (en) * 2015-05-06 2022-03-07 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
EP3307307A4 (en) 2015-06-09 2019-05-01 The Board of Regents of the University of Oklahoma COMPOSITIONS AND TREATMENTS FOR HAEMOPHILUS INFLUENZAE
EP3868406A1 (en) 2015-06-24 2021-08-25 Immodulon Therapeutics Limited A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
CN108026154B (zh) 2015-07-01 2022-03-08 伊玛提克斯生物技术有限公司 用于卵巢癌和其他癌症免疫治疗的新型肽和肽组合物
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
MD3319985T2 (ro) * 2015-07-06 2021-01-31 Immatics Biotechnologies Gmbh Noi peptide și combinații de peptide pentru utilizare în imunoterapie împotriva cancerului esofagian și a altor cancere
GB201512369D0 (en) * 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
CN115925806A (zh) 2015-08-28 2023-04-07 伊玛提克斯生物技术有限公司 用于各种癌症免疫治疗的新型肽、肽组合物和支架
GB201515321D0 (en) 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
US10709758B2 (en) 2015-09-03 2020-07-14 The Board Of Regents Of The University Of Oklahoma Peptide inhibitors of clostridium difficile toxin B (TcdB) toxin
WO2017070237A1 (en) 2015-10-19 2017-04-27 University Of Maryland, Baltimore Methods for generating engineered human primary blood dendritic cell lines
WO2017099712A1 (en) 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
SG11201804957VA (en) 2015-12-16 2018-07-30 Gritstone Oncology Inc Neoantigen identification, manufacture, and use
US10604759B2 (en) 2016-01-15 2020-03-31 City Of Hope Targeting glioblastoma stem cells through the TLX-TET3 axis
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
CN105664134B (zh) * 2016-03-13 2019-04-26 浙江药苑生物科技有限公司 一种用于治疗骨癌的药物组合物
GB201604494D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
GB201604490D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
ES2930681T3 (es) 2016-03-16 2022-12-20 Immatics Biotechnologies Gmbh Linfocitos T transfectados y receptores de linfocito T para el uso en la inmunoterapia contra el cáncer
KR102411975B1 (ko) * 2016-04-06 2022-06-22 이매틱스 바이오테크놀로지스 게엠베하 Aml 및 다른 암에 대한 면역요법에 사용하기 위한 펩티드 및 펩티드의 조합
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2017194170A1 (en) * 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
KR101881300B1 (ko) 2016-06-30 2018-07-25 영남대학교 산학협력단 아조피라졸 화합물 및 은 촉매 반응을 이용한 이의 신규한 합성방법
ES2950435T3 (es) * 2016-10-03 2023-10-10 Ottawa Hospital Res Inst Composiciones y métodos para mejorar el crecimiento, la propagación y la eficacia oncolítica e inmunoterapéutica de virus oncolíticos de ARN
CN110022906A (zh) 2016-11-04 2019-07-16 蓝鸟生物公司 抗bcma car t细胞组合物
KR102639592B1 (ko) 2016-12-08 2024-02-21 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
DK3558339T5 (da) 2016-12-22 2024-09-02 Cue Biopharma Inc T-celle-modulerende multimere polypeptider og fremgangsmåder til anvendelse deraf
CA3039772C (en) 2017-01-06 2020-08-25 Eutilex Co., Ltd. Anti-human 4-1bb antibodies and uses thereof
GB201702863D0 (en) * 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
WO2018160498A1 (en) * 2017-02-28 2018-09-07 Lyten, Inc. Mixed allotrope particulate carbon films and carbon fiber mats
PE20191842A1 (es) 2017-05-08 2019-12-31 Gritstone Oncology Inc Vectores de neoantigeno de alfavirus
CN107058596A (zh) * 2017-06-19 2017-08-18 上海市第十人民医院 一种与恶性胶质瘤诊断相关的标志物及其应用
CN107034305A (zh) * 2017-06-19 2017-08-11 上海市第十人民医院 恶性胶质瘤的一种诊断标志物
AU2018348165A1 (en) 2017-10-10 2020-05-21 Gritstone Bio, Inc. Neoantigen identification using hotspots
IL274799B1 (en) 2017-11-22 2025-01-01 Gritstone Bio Inc Reducing epitope binding presentation for neoantigens
EP3725092A4 (en) 2017-12-14 2021-09-22 FloDesign Sonics, Inc. DRIVE AND CONTROL UNIT FOR ACOUSTIC CONVERTER
CN111344402A (zh) * 2017-12-14 2020-06-26 Ezy生物科技有限公司 受试者特异性肿瘤抑制细胞及其用途
RS63873B1 (sr) * 2018-04-11 2023-02-28 Enterome S A Antigenski peptidi za prevenciju i lečenje raka
CN108715832B (zh) * 2018-06-01 2020-11-10 段海峰 一种抑制肿瘤生长的间充质干细胞及制备方法和应用
WO2020110154A1 (en) * 2018-11-30 2020-06-04 Bharat Biotech International Limited A chimeric therapeutic vaccine
RU2706554C1 (ru) * 2018-12-13 2019-11-19 Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ Способ создания противоинфекционной иммунологической защиты к Salmonella typhimurium и Listeria monocytogenes с помощью трансгенеза Т-лимфоцитов
CN109796536B (zh) * 2019-02-22 2021-09-17 上海尚泰生物技术有限公司 一种靶向胶质母细胞瘤多种抗原表位的ctl的制备方法
US12214027B2 (en) 2019-03-29 2025-02-04 Intervet Inc. Stabilisation of live mollicutes bacteria in a liquid composition
GB2617512B (en) 2019-04-05 2023-12-27 Earli Inc Improved methods and compositions for synthetic biomarkers
JP7150289B2 (ja) 2019-05-28 2022-10-11 ペイジ．エーアイ インコーポレイテッド デジタル病理学のための処理された画像に関するスライドを調製するために画像を処理するためのシステムおよび方法
CA3140019A1 (en) 2019-05-30 2020-12-03 Gritstone Bio, Inc. Modified adenoviruses
CN110579457B (zh) * 2019-09-20 2021-11-02 郑州大学第一附属医院 波形蛋白特异响应性荧光探针及其制备方法和应用
CN112824427B (zh) * 2019-11-18 2022-06-24 杨小骏 一种抑制胶质瘤的短肽及其应用
EP4087602A4 (en) * 2020-01-10 2023-11-29 The Brigham & Women's Hospital, Inc. METHODS AND COMPOSITIONS FOR DELIVERING IMMUNOTHERAPEUTIC ACTIVE INGREDIENTS THROUGH THE BLOOD-BRAIN BARRIER TO TREAT BRAIN TUMORS
CN113318225B (zh) * 2020-02-28 2024-01-19 无锡派列博生物医药科技有限公司 肿瘤免疫增强剂及其制法和应用
CN113621025A (zh) * 2020-03-18 2021-11-09 北京鼎成肽源生物技术有限公司 一种乳腺癌靶标抗原、乳腺癌靶标抗原刺激培养的ctl细胞及其应用
EP4127188A4 (en) 2020-03-31 2024-08-21 Walking Fish Therapeutics MODIFIED B CELLS AND METHODS OF USE THEREOF
CN115552017A (zh) * 2020-03-31 2022-12-30 步行鱼治疗学公司 经修饰的b细胞及其使用方法
JP2023541108A (ja) 2020-08-06 2023-09-28 グリットストーン バイオ インコーポレイテッド マルチエピトープワクチンカセット
KR102711471B1 (ko) 2020-08-14 2024-09-30 서울대학교산학협력단 B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물
CA3190707A1 (en) * 2020-08-28 2022-03-03 Torigen Pharmaceuticals, Inc. Immune memory enhanced preparations and uses thereof
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
WO2023192820A2 (en) * 2022-03-30 2023-10-05 Iogenetics, Llc Tumor-associated antigens in brain tumors
PL441229A1 (pl) * 2022-05-19 2023-11-20 Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk Zaprojektowane, syntetyczne peptydy, zawierające je kompozycje i sposoby ich zastosowania w leczeniu glejaków złośliwych

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
LU88257I2 (uk) 1978-12-22 1994-02-03
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US5338839A (en) * 1988-04-12 1994-08-16 Massachusetts Institute Of Technology DNA encoding nestin protein
GB2267257A (en) 1992-05-14 1993-12-01 Ford Motor Co A vehicle load compartment liner.
KR100235089B1 (en) 1992-05-14 1999-12-15 Mitsui Chemicals Inc Ptp or blister packaging articles and packaging material therefor
US6193969B1 (en) 1993-06-03 2001-02-27 Protherics Inc. Antibody fragments in therapy
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
EP0879282B1 (en) 1996-01-17 2003-07-02 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
TW575583B (en) * 1996-04-24 2004-02-11 Akzo Nobel Nv Novel peptides suitable for use in antigen specific immunosuppressive therapy
CA2262007A1 (en) * 1996-07-22 1998-01-29 The Rockefeller University Env-glycoprotein vaccine for protection of htlv-i and -ii infection
WO1998031797A1 (en) 1997-01-15 1998-07-23 Zymogenetics, Inc. Zppar6, human tailless nuclear hormone receptor (tlx receptor)
WO1998036062A1 (en) * 1997-02-13 1998-08-20 Smithkline Beecham Plc Neural cell adhesion molecule splicing variants
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CA2311574A1 (en) * 1997-12-02 1999-06-10 Medarex, Inc. Cells expressing anti-fc receptor binding components
US7258860B2 (en) * 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CA2328992A1 (en) * 1998-04-27 1999-11-04 Northwest Hospital Nr-cam gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors
US20030082586A1 (en) * 1999-06-29 2003-05-01 Millennium Pharmaceuticals, Inc. Antibodies having diagnostic, preventive, therapeutic, and other uses
CA2393652A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20020042386A1 (en) * 2000-01-31 2002-04-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
ATE472601T1 (de) 2000-03-27 2010-07-15 Technion Res And Dev Of Founda Einkettige haupthistokompatibilitätskomplexe der klasse i (mhc-i), kodierende konstrukte und methoden ihrer erzeugung
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
AU2001279581A1 (en) * 2000-09-06 2002-03-22 Friederike Muller Medicament comprising a dna sequence, which codes for the rna-binding koc protein, and comprising a koc protein or dna sequence of the koc promoter
EP1356048A2 (en) * 2000-12-04 2003-10-29 Argonex Pharmaceuticals Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2002046767A2 (en) * 2000-12-08 2002-06-13 Oxford Glycosciences (Uk) Ltd. Diagnosis and treatment of alzheimer's disease
AU2002254482A1 (en) * 2001-03-19 2002-10-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
CA2364106A1 (fr) * 2001-11-30 2003-05-30 Christopher Gillberg Polynucleotide et proteine impliques dans la synaptogenese, variants de ceux-ci, et leurs applications therapeutiques et diagnostiques
US6589642B1 (en) 2001-12-21 2003-07-08 Kloeckner Pentaplast Of America, Inc. Three part high moisture barrier for packages
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US6992176B2 (en) * 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1485075A4 (en) 2002-02-20 2006-04-26 Dyax Corp MHC-PEPTIDE COMPLEX BINDING LIGANDS
WO2004015390A2 (en) * 2002-08-09 2004-02-19 Applera Corporation Lung cancer target proteins and use thereof
JP4721633B2 (ja) * 2002-10-11 2011-07-13 財団法人癌研究会 血小板凝集促進活性を有する物質
WO2004067029A1 (fr) * 2002-12-27 2004-08-12 Shenzhen Tsinghua Yuanxing Bio-Pharm Science & Technology Co., Ltd. Procede de preparation d'un vaccin et vaccins antitumoraux
US20060241166A1 (en) 2003-04-04 2006-10-26 Pharmacyclica, Inc. Sapphyrins and uses thereof
US7273980B2 (en) 2004-01-13 2007-09-25 Wardle Scott A Position and velocity transducer using a phonograph disc and turntable
EP1712620A4 (en) * 2004-01-23 2008-05-28 Greenpeptide Co Ltd EGF (EPIDERMAL GROWTH FACTOR) RECEPTOR-ORGANIC PEPTIDE
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006026569A2 (en) * 2004-08-27 2006-03-09 Northeastern University Comprehensive characterization of complex proteins at trace levels
SI1642905T1 (sl) * 2004-10-02 2009-04-30 Immatics Biotechnologies Gmbh Imunogeni T-pomagalni epitop iz humanega tumornega antigena in imunoterapevtski postopki, ki uporabljajo navedeni epitop
ES2534752T3 (es) * 2004-12-07 2015-04-27 Toray Industries, Inc. Nuevo péptido antigénico contra el cáncer y utilización del mismo
KR100809410B1 (ko) * 2005-07-06 2008-03-05 주식회사 브레인가드 줄기세포 분화 유도용 조성물 및 그의 용도
EP1760089B1 (en) * 2005-09-05 2009-08-19 Immatics Biotechnologies GmbH Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine
DE602005020047D1 (de) 2005-09-05 2010-04-29 Immatics Biotechnologies Gmbh Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden
EP1938104A2 (en) 2005-10-17 2008-07-02 Institute for Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
WO2007072494A1 (en) 2005-12-23 2007-06-28 Naik Praful Ramchandra Metallized packaging blister container
AU2007298494B2 (en) * 2006-09-21 2013-09-26 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
CA2700573C (en) * 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
EP2164859A4 (en) * 2007-03-06 2012-06-06 Iterative Therapeutics Inc METHODS AND COMPOSITIONS USING POLYMERIC IMMUNOGLOBULIN HYBRID PROTEINS
US8747855B2 (en) * 2008-04-09 2014-06-10 Technion Research & Development Foundation Limited Anti human immunodeficiency antibodies and uses thereof
KR101184869B1 (ko) * 2008-04-24 2012-09-20 이매틱스 바이오테크놀로지스 게엠베하 백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 신규한 제형
DE602008000891D1 (de) * 2008-04-30 2010-05-12 Immatics Biotechnologies Gmbh Neuartige Formulierungen von Tumor-assoziierten Peptiden, welche an menschliche Leukozytenantigene der Klasse I oder II für Impfungen binden
ES2536465T3 (es) 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201021289D0 (en) 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
SG10202001285XA (en) * 2014-05-28 2020-04-29 Nono Inc Chloride salt of tat-nr2b9c
KR20180135481A (ko) 2016-04-21 2018-12-20 이매틱스 바이오테크놀로지스 게엠베하 흑색종 및 기타 암에 대한 면역요법
WO2019051001A1 (en) * 2017-09-06 2019-03-14 California Institute Of Technology SIGNALING AND BIFUNCTIONAL RECEPTORS HAVING ANTIGENS (SABR)

Also Published As

Publication number Publication date
HRP20201228T1 (hr) 2021-02-05
HRP20201015T1 (hr) 2020-10-16
ES2710608T3 (es) 2019-04-26
PT3069728T (pt) 2019-02-13
US10047124B2 (en) 2018-08-14
US11136352B2 (en) 2021-10-05
EP3132801B1 (en) 2019-10-30
PT3111952T (pt) 2019-02-05
US11208434B2 (en) 2021-12-28
CY1118702T1 (el) 2017-07-12
DK2341927T3 (en) 2016-08-15
US20190010190A1 (en) 2019-01-10
PL2331118T3 (pl) 2017-05-31
DK2172212T3 (da) 2016-12-19
SI3120870T1 (sl) 2020-08-31
US10227381B2 (en) 2019-03-12
EP3069728A1 (en) 2016-09-21
JP2017018101A (ja) 2017-01-26
JP5883476B2 (ja) 2016-03-15
SI3120868T1 (sl) 2020-08-31
EP3111952B1 (en) 2018-10-31
CY1119744T1 (el) 2018-06-27
HRP20190202T1 (hr) 2019-03-22
SI3132801T1 (sl) 2020-03-31
US20210238227A1 (en) 2021-08-05
JP6297632B2 (ja) 2018-03-20
PT3120870T (pt) 2020-07-01
PL2172212T3 (pl) 2017-04-28
MX2011003540A (es) 2011-06-20
EP2172211B1 (en) 2014-12-03
CY1123113T1 (el) 2021-10-29
JP5855940B2 (ja) 2016-02-09
CY1123098T1 (el) 2021-10-29
CA2739384C (en) 2017-05-02
JP2017018102A (ja) 2017-01-26
KR101687840B1 (ko) 2016-12-19
EP2331118A1 (en) 2011-06-15
DK3132801T3 (da) 2020-02-10
EP2172211A1 (en) 2010-04-07
US20100158931A1 (en) 2010-06-24
HUE049364T2 (hu) 2020-09-28
DK3124043T3 (da) 2020-05-04
BRPI0920759A2 (pt) 2016-03-08
NZ624533A (en) 2015-09-25
DK3120870T3 (da) 2020-06-22
KR20110074894A (ko) 2011-07-04
EP2172212A3 (en) 2010-04-14
KR102133402B1 (ko) 2020-07-14
HUE042115T2 (hu) 2019-06-28
US10100085B2 (en) 2018-10-16
US20110002963A1 (en) 2011-01-06
TR201900852T4 (tr) 2019-02-21
CY1122677T1 (el) 2021-03-12
US10047123B2 (en) 2018-08-14
EP3120870B1 (en) 2020-04-01
US8119139B2 (en) 2012-02-21
ES2708654T3 (es) 2019-04-10
US8895514B2 (en) 2014-11-25
PL3069728T3 (pl) 2019-05-31
PL3120869T3 (pl) 2021-01-25
DK2172211T3 (en) 2015-02-16
US20130004456A1 (en) 2013-01-03
DK3120868T3 (da) 2020-06-22
LT3069728T (lt) 2019-02-11
HK1159526A1 (zh) 2012-08-03
EA023378B1 (ru) 2016-05-31
EA201100587A1 (ru) 2011-10-31
JP2017023136A (ja) 2017-02-02
CA2936887C (en) 2019-11-12
ES2612466T3 (es) 2017-05-17
HRP20150223T8 (hr) 2015-07-03
SI3106175T1 (sl) 2020-08-31
US20210261614A1 (en) 2021-08-26
EP2172212A2 (en) 2010-04-07
DK2331118T5 (en) 2017-06-19
PL2172211T3 (pl) 2015-05-29
EP3120869A1 (en) 2017-01-25
US20160376313A1 (en) 2016-12-29
PT3120868T (pt) 2020-07-16
SI2341927T1 (sl) 2016-08-31
UA125277C2 (uk) 2022-02-16
EP3111952A1 (en) 2017-01-04
PL3111952T3 (pl) 2019-04-30
HUE031030T2 (en) 2017-06-28
JP6294914B2 (ja) 2018-03-14
CA2936870A1 (en) 2010-04-08
RS60338B1 (sr) 2020-07-31
CA2936920A1 (en) 2010-04-08
EP2331118B1 (en) 2016-10-26
LT3111952T (lt) 2018-12-27
ES2584245T3 (es) 2016-09-26
EP3132801A1 (en) 2017-02-22
HRP20150223T1 (hr) 2015-06-05
HRP20200722T1 (hr) 2020-10-16
EP3069728B1 (en) 2018-11-14
PL2341927T3 (pl) 2016-11-30
HRP20200988T1 (hr) 2020-10-16
US10906936B2 (en) 2021-02-02
RS55543B1 (sr) 2017-05-31
SI3069728T1 (sl) 2019-03-29
AU2009300088B2 (en) 2014-09-04
BRPI0920791A2 (pt) 2019-12-10
KR20110082155A (ko) 2011-07-18
AU2009300088A1 (en) 2010-04-08
SI2172212T1 (sl) 2016-12-30
CY1123526T1 (el) 2022-03-24
HUE029360T2 (en) 2017-02-28
HUE049367T2 (hu) 2020-09-28
PL3120870T3 (pl) 2020-07-27
RS60006B1 (sr) 2020-04-30
RS60656B1 (sr) 2020-09-30
DK3120869T3 (da) 2020-08-10
HRP20160915T1 (hr) 2016-10-07
EP2172212B1 (en) 2016-10-05
EA023013B1 (ru) 2016-04-29
PT2172211E (pt) 2015-03-09
PL3132801T3 (pl) 2020-06-15
LT3120870T (lt) 2020-08-10
SI2172211T1 (sl) 2015-03-31
RS58229B1 (sr) 2019-03-29
PL3120868T3 (pl) 2020-08-24
NZ603016A (en) 2014-05-30
US8961985B2 (en) 2015-02-24
EP3124043A1 (en) 2017-02-01
RS53782B1 (en) 2015-06-30
US10919931B2 (en) 2021-02-16
LT2331118T (lt) 2016-12-27
ES2788129T3 (es) 2020-10-20
HRP20201025T1 (hr) 2020-12-25
EP2341927A2 (en) 2011-07-13
US10046037B2 (en) 2018-08-14
CA2936924C (en) 2019-07-16
SI3120869T1 (sl) 2020-10-30
CN102170901B (zh) 2015-01-07
KR20220058655A (ko) 2022-05-09
MX2011003539A (es) 2011-06-20
HUE051030T2 (hu) 2021-01-28
CY1121098T1 (el) 2019-12-11
HUE050428T2 (hu) 2020-12-28
ES2770090T3 (es) 2020-06-30
WO2010037513A1 (en) 2010-04-08
US20130309193A1 (en) 2013-11-21
US20160376317A1 (en) 2016-12-29
CA2936869A1 (en) 2010-04-08
NZ591855A (en) 2012-11-30
AU2009300087A1 (en) 2010-04-08
KR101883426B1 (ko) 2018-07-31
US12234298B2 (en) 2025-02-25
SI3111952T1 (sl) 2019-01-31
EA032437B1 (ru) 2019-05-31
US20160376314A1 (en) 2016-12-29
US8318677B2 (en) 2012-11-27
CA2936887A1 (en) 2010-04-08
PT3120869T (pt) 2020-09-22
HUE047365T2 (hu) 2020-04-28
PT2172212T (pt) 2016-12-22
LT3120869T (lt) 2020-11-10
EP3106175A1 (en) 2016-12-21
RS55043B1 (sr) 2016-12-30
US20210347822A1 (en) 2021-11-11
EP3120870A1 (en) 2017-01-25
LT3120868T (lt) 2020-08-10
CY1123089T1 (el) 2021-10-29
PT2341927T (pt) 2016-08-02
KR102392070B1 (ko) 2022-04-29
HRP20182151T1 (hr) 2019-02-08
RS58443B1 (sr) 2019-04-30
PT2331118T (pt) 2017-02-06
HRP20170115T1 (hr) 2017-03-24
CA2739387C (en) 2019-10-29
CA2739384A1 (en) 2010-04-08
ES2804723T3 (es) 2021-02-09
US10941181B2 (en) 2021-03-09
EA201401104A1 (ru) 2015-05-29
ES2802226T3 (es) 2021-01-18
CA2936868A1 (en) 2010-04-08
KR20180088494A (ko) 2018-08-03
LT3124043T (lt) 2020-07-10
US20160376312A1 (en) 2016-12-29
US9993540B2 (en) 2018-06-12
CN102170901A (zh) 2011-08-31
HUE041446T2 (hu) 2019-05-28
WO2010037514A2 (en) 2010-04-08
RS60386B1 (sr) 2020-07-31
JP2014239681A (ja) 2014-12-25
CY1116302T1 (el) 2017-02-08
US12221493B2 (en) 2025-02-11
US20160376316A1 (en) 2016-12-29
SI2331118T1 (sl) 2017-01-31
TR201900809T4 (tr) 2019-02-21
CA2936920C (en) 2019-12-03
PL3106175T3 (pl) 2020-08-24
JP2016047825A (ja) 2016-04-07
CA2936982C (en) 2019-12-03
ES2802227T3 (es) 2021-01-18
MX338294B (es) 2016-04-11
US20210253637A1 (en) 2021-08-19
LT3106175T (lt) 2020-08-10
WO2010037514A3 (en) 2010-06-03
BRPI0920791B1 (pt) 2022-01-18
DK2331118T3 (da) 2017-01-09
EP2341927B1 (en) 2016-05-04
KR20200085381A (ko) 2020-07-14
DK3111952T3 (en) 2019-01-28
JP6214066B2 (ja) 2017-10-18
LT3132801T (lt) 2020-02-10
JP6367266B2 (ja) 2018-08-01
NZ591882A (en) 2012-12-21
EP3106175B1 (en) 2020-04-01
JP6150859B2 (ja) 2017-06-21
US20170326217A1 (en) 2017-11-16
PT3106175T (pt) 2020-07-01
JP2012504563A (ja) 2012-02-23
JP2016145210A (ja) 2016-08-12
HRP20161504T1 (hr) 2016-12-30
KR101756488B1 (ko) 2017-07-11
HUE049366T2 (hu) 2020-09-28
EP3120869B1 (en) 2020-07-22
HUE030296T2 (en) 2017-04-28
ES2536465T3 (es) 2015-05-25
CA2936982A1 (en) 2010-04-08
US20160376315A1 (en) 2016-12-29
UA103202C2 (uk) 2013-09-25
RS60381B1 (sr) 2020-07-31
ES2819244T3 (es) 2021-04-15
US8653035B2 (en) 2014-02-18
DK3106175T3 (da) 2020-06-22
CA2936870C (en) 2019-11-26
US20120141517A1 (en) 2012-06-07
JP5753783B2 (ja) 2015-07-22
DK3069728T3 (en) 2019-02-25
US20160355550A1 (en) 2016-12-08
HRP20201025T8 (hr) 2022-01-07
ES2788129T8 (es) 2020-11-04
HRP20200110T1 (hr) 2020-05-15
JP2012504393A (ja) 2012-02-23
CA2936869C (en) 2019-08-06
AU2009300087B2 (en) 2014-09-04
US20150125478A1 (en) 2015-05-07
SI3124043T1 (sl) 2020-07-31
CY1121258T1 (el) 2020-05-29
HK1161106A1 (zh) 2012-08-24
JP2017029135A (ja) 2017-02-09
RS55531B1 (sr) 2017-05-31
ES2607460T3 (es) 2017-03-31
JP2017000148A (ja) 2017-01-05
HRP20201015T8 (hr) 2022-01-21
EP3124043B1 (en) 2020-04-29
PL3124043T3 (pl) 2020-07-27
EP3120868B1 (en) 2020-04-08
PT3132801T (pt) 2020-02-04
LT2172212T (lt) 2016-11-10
CY1122913T1 (el) 2021-10-29
CN102170900A (zh) 2011-08-31
RS60385B1 (sr) 2020-07-31
CN102170900B (zh) 2016-10-26
CA2936868C (en) 2019-10-22
CA2936924A1 (en) 2010-04-08
EA201100586A1 (ru) 2011-10-31
CN106986919A (zh) 2017-07-28
JP6294913B2 (ja) 2018-03-14
CA2739387A1 (en) 2010-04-08
PT3124043T (pt) 2020-05-12
KR20160103558A (ko) 2016-09-01
BRPI0920791B8 (pt) 2022-02-15
EP3120868A1 (en) 2017-01-25

Similar Documents

Publication Publication Date Title
UA110599C2 (uk) Пептид для імунотерапії пухлин, включаючи нейрональні пухлини та пухлини мозку
UA110473C2 (uk) Спосіб лікування раку за допомогою пухлиноасоційованого антигену, отриманого із цикліну d1
MX337456B (es) Vacunas peptidicas para canceres que expresan antigenos asociados con tumores.
RU2016146198A (ru) Терапевтические dll4-связывающие белки
MX348360B (es) Anticuerpo biespecifico psmaxcd3 de simple cadena especifico de especies cruzadas.
IN2014CN02050A (uk)
MX2011003502A (es) Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies.
CO6341638A2 (es) Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas y metodos para su uso
MX359234B (es) Inmunoterapia de celulas t objetivadas en ciclina a1 para cancer.
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
NZ596735A (en) Recombinant production of peptides
NZ597692A (en) Anti-IGF antibodies
NZ562436A (en) Toll-like receptor 14 (TLR14) and use thereof
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
EP2589658A4 (en) PARTIAL REGION POLYPEPTIDE OF REIC / DKK-3 PROTEIN
NZ706884A (en) Fc gamma receptor iib variants
MX2015007421A (es) Proteinas de tipo espiral enrollada modificadas que tienen propiedades mejoradas.
WO2011135222A3 (fr) Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles
AR128395A2 (es) Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9
PH12012502520A1 (en) Plants having enhanced yield-related traits and method for making the same
MX2009007261A (es) Vacuna de peptido foxp3.
EP4353256A3 (en) Induction of cross-reactive cellular response against rhinovirus antigens
IN2012DN05886A (uk)
MX2010005816A (es) Epítopos de péptido de stat3.
EA200901441A1 (ru) Новые молекулы антител и нуклеиновых кислот, связывающиеся с грибным белком теплового шока hsp90